Wutah dodolan YoY sajrone 12 wulan kepungkur: ALX Oncology Holdings (ALXO)

Oncology center capacity and plant capacity reservations are driving the growth of ALX Oncology Holdings (ALXO), as illustrated by the GURU.Markets terminal on the TTM year-over-year sales growth percentage chart. The 0.00 metric reflects current dynamics based on the production of proteins for tumor unmasking. Operational resilience is maintained through a network of external CDMO partners in California, which minimizes downtime risks.
ALX Oncology (ALXO) - rincian metrik lan laporan keuangan

For ALX Oncology Holdings (ALXO), the commercialization potential of evorpacept correlates directly with the YoY sales growth trend over the last four quarters. This metric measures the pace of revenue expansion, smoothing out short-term fluctuations via a rolling window. The calculation is based on comparing the total revenue of the current twelve months with the same period last year. A positive trend confirms business scaling; however, buying at extreme values creates the risk of overpaying for the asset.